Target
Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) 344D]
Ligand
BDBM176802
Substrate
n/a
Meas. Tech.
MKNK1 Kinase High ATP Assay
pH
7.5±n/a
IC50
98±n/a nM
Comments
extracted
Citation
 Klar, UWortmann, LGraham, KPuehler, FSülzle, DKettschau, GLienau, P Substituted thiazolopyrimidines US Patent  US9675612 Publication Date 6/13/2017 
Target
Name:
Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) 344D]
Synonyms:
Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) 344D] | Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D] | MAP kinase signal-integrating kinase 1 (MNK1) (T344D) | MAP kinase-interacting serine/threonine-protein kinase 1 (MKNK1) | MAP kinase-interacting serine/threonine-protein kinase 1 (MKNK1) (T344D) | MAP kinase-interacting serine/threonine-protein kinase 1 (MKNK1)(T344D) | MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D] | MAP kinase-interacting serine/threonine-protein kinase 1 (T344D) | MKNK1 | MKNK1 (aa 1-424) T344D | MKNK1_HUMAN | MNK1 | MNK1a
Type:
Protein
Mol. Mass.:
47416.00
Organism:
Homo sapiens (Human)
Description:
Q9BUB5-2 with T344D
Residue:
424
Sequence:
MVSSQKLEKPIEMGSSEPLPIADGDRRRKKKRRGRATDSLPGKFEDMYKLTSELLGEGAYAKVQGAVSLQNGKEYAVKIIEKQAGHSRSRVFREVETLYQCQGNKNILELIEFFEDDTRFYLVFEKLQGGSILAHIQKQKHFNEREASRVVRDVAAALDFLHTKGIAHRDLKPENILCESPEKVSPVKICDFDLGSGMKLNNSCTPITTPELTTPCGSAEYMAPEVVEVFTDQATFYDKRCDLWSLGVVLYIMLSGYPPFVGHCGADCGWDRGEVCRVCQNKLFESIQEGKYEFPDKDWAHISSEAKDLISKLLVRDAKQRLSAAQVLQHPWVQGQAPEKGLPDPQVLQRNSSTMDLTLFAAEAIALNRQLSQHEENELAEEPEALADGLCSMKLSPPCKSRLARRRALAQAGRGEDRSPPTAL
  
Inhibitor
Name:
BDBM176802
Synonyms:
US9675612, 39 N-[2-(Dimethylamino)-2-oxoethyl]-N-methyl-7-{[6-(propan-2-yloxy)-1H-indazol-5-yl]amino}[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide
Type:
Small organic molecule
Emp. Form.:
C21H24N8O3S
Mol. Mass.:
468.532
SMILES:
CC(C)Oc1cc2[nH]ncc2cc1Nc1ncnc2sc(nc12)C(=O)N(C)CC(=O)N(C)C
Structure:
Search PDB for entries with ligand similarity: